Peripheral and Central GLP-1 Receptor Populations Mediate the Anorectic Effects of Peripherally Administered GLP-1 Receptor Agonists, Liraglutide and Exendin-4
Open Access
- 21 June 2011
- journal article
- other
- Published by The Endocrine Society in Endocrinology
- Vol. 152 (8), 3103-3112
- https://doi.org/10.1210/en.2011-0174
Abstract
The long-acting glucagon-like peptide-1 receptor (GLP-1R) agonists, exendin-4 and liraglutide, suppress food intake and body weight. The mediating site(s) of action for the anorectic effects produced by peripheral administration of these GLP-1R agonists are not known. Experiments addressed whether food intake suppression after ip delivery of exendin-4 and liraglutide is mediated exclusively by peripheral GLP-1R or also involves direct central nervous system (CNS) GLP-1R activation. Results showed that CNS delivery [third intracerebroventricular (3rd ICV)] of the GLP-1R antagonist exendin-(9–39) (100 μg), attenuated the intake suppression by ip liraglutide (10 μg) and exendin-4 (3 μg), particularly at 6 h and 24 h. Control experiments show that these findings appear to be based neither on the GLP-1R antagonist acting as a nonspecific competing orexigenic signal nor on blockade of peripheral GLP-1R via efflux of exendin-(9–39) to the periphery. To assess the contribution of GLP-1R expressed on subdiaphragmatic vagal afferents to the anorectic effects of liraglutide and exendin-4, food intake was compared in rats with complete subdiaphragmatic vagal deafferentation and surgical controls after ip delivery of the agonists. Both liraglutide and exendin-4 suppressed food intake at 3 h, 6 h, and 24 h for controls; for subdiaphragmatic vagal deafferentation rats higher doses of the GLP-1R agonists were needed for significant food intake suppression, which was observed at 6 h and 24 h after liraglutide and at 24 h after exendin-4. Conclusion: Food intake suppression after peripheral administration of exendin-4 and liraglutide is mediated by activation of GLP-1R expressed on vagal afferents as well as direct CNS GLP-1R activation.Keywords
This publication has 54 references indexed in Scilit:
- Role of the glucagon-like-peptide-1 receptor in the control of energy balancePhysiology & Behavior, 2010
- Liraglutide for weight loss in obese peopleThe Lancet, 2010
- Exenatide and weight lossNutrition, 2010
- The Extrapancreatic Effects of Glucagon-Like Peptide-1 and Related PeptidesJournal of Clinical Endocrinology & Metabolism, 2009
- Endogenous Hindbrain Glucagon-Like Peptide-1 Receptor Activation Contributes to the Control of Food Intake by Mediating Gastric Satiation SignalingEndocrinology, 2009
- Evidence that Intestinal Glucagon-Like Peptide-1 Plays a Physiological Role in SatietyEndocrinology, 2008
- Intrameal Hepatic Portal and Intraperitoneal Infusions of Glucagon-Like Peptide-1 Reduce Spontaneous Meal Size in the Rat via Different MechanismsEndocrinology, 2008
- Caudal Brainstem Processing Is Sufficient for Behavioral, Sympathetic, and Parasympathetic Responses Driven by Peripheral and Hindbrain Glucagon-Like-Peptide-1 Receptor StimulationEndocrinology, 2008
- Exendin-4 and exendin-(9–39)NH2: agonist and antagonist, respectively, at the rat parietal cell receptor for glucagon-like peptide-1-(7–36)NH2European Journal of Pharmacology: Molecular Pharmacology, 1994
- An investigation of tolerance to the actions of leptogenic and anorexigenic drugs in miceLife Sciences, 1987